Search

Displaying results 5601 - 5610 of 10000 in total
  1. Drug

    Altropane I-123

    go.drugbank.com/drugs/DB15144
    Investigational

    Altropane I-123 is under investigation in clinical trial NCT01950468 (A Cross-Over, Multi-Center Trial to Evaluate the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the

  2. Drug

    Aluminum zirconium pentachlorohydrate

    go.drugbank.com/drugs/DB11147
    Approved

    Its main mechanism of action is through blocking the pores via formation of polymer complex and preventing sweat from leaving the body.

  3. Drug

    Methylone

    go.drugbank.com/drugs/DB19192
    Investigational

    Methylone is under investigation in clinical trial NCT05741710 (A Study to Assess the use of Methylone in the Treatment of PTSD).

  4. Drug

    OPC-28326

    go.drugbank.com/drugs/DB05461
    Experimental

    It is the only clinical compound with this profile. It is currently being investigated in the treatment of peripheral vascular diseases and Raynaud's syndrome. … At low doses, OPC 28326 selectively vasodilates the femoral arterial bed due to its inhibitory action at alpha-2-adrenoceptors while having minimal action on systemic blood pressure, heart rate and coronary

  5. Drug

    Telazorlimab

    go.drugbank.com/drugs/DB16374
    Investigational

    Telazorlimab is under investigation in clinical trial NCT03568162 (Phase 2b Study to Evaluate the Efficacy and Safety of ISB 830 in Adults With Moderate to Severe Atopic Dermatitis).

  6. Drug

    Pegmusirudin

    go.drugbank.com/drugs/DB19220
    Investigational

    Pegmusirudin is under investigation in clinical trial NCT00074620 (A Clinical Study to Assess the Safety of Peg-hirudin (SPP200) Compared to Heparin in Patients Who Are on Haemodialysis).

  7. Drug

    Firocoxib

    go.drugbank.com/drugs/DB09217
    ExperimentalVet approved

    It currently approved for veterinary use in dogs and horses under the brand names Equioxx and Previcox. Firocoxib was the first COX-2 inhibitor approved by the U.S.

  8. Drug

    CRx-139

    go.drugbank.com/drugs/DB05744
    Experimental

    The synergistic combination containing low doses of the glucocorticoid steroid prednisolone and the antidepressant paroxetine. … It is a dissociated steroid designed to enhance the immuno-modulatory activity of a low-dose glucocorticoid steroid without a comparable increase in steroid-related side effects.

  9. Drug

    Rice bran oil

    go.drugbank.com/drugs/DB11293
    ApprovedInvestigational

    Rice bran oil is classified as an indirect additive used in food contact substances by the FDA. … The major constituents of rice bran oil include myristic acid, palmitic acid, stearic acid, oleic acid, linoleic acid, and α-Linolenic acid.

  10. Drug

    Moxazocine

    go.drugbank.com/drugs/DB20517
    Experimental

    The usage of the INN stem '-azocine' in the name indicates that Moxazocine is a narcotic antagonist/agonist related to 6,7-benzomorphan. Moxazocine has a monoisotopic molecular weight of 287.19 Da.